ClinicalTrials.gg
CompletedNCT00510146Updated May 26, 2011Results posted

Olanzapine Treatment of Patients With Bipolar I Disorder

A Phase 3 interventional study of Olanzapine and Placebo in Depression, Bipolar, sponsored by Eli Lilly and Company. Completed at 16 sites in 3 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2011-05-26.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
514
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing olanzapine in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Olanzapine · Bipolar Disorder.

Enrollment
Largest of 28
514 · median 120
Started
2007
with 3 others
Phase 3
7 of 28
none open now
Registered
21st of 28
by date
Lead sponsor
13 of 28
Eli Lilly and Company

Among the 28 studies testing olanzapine in Bipolar Disorder, this one has the largest enrollment, is one of 4 that started in 2007, is one of 7 in phase 3, and was the 21st registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

None of the 28 studies testing olanzapine in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →

About olanzapine

Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies testing olanzapine in Bipolar Disorder as a file.
02

Study summary

The purpose of this study is to assess whether olanzapine is superior to placebo in patients with bipolar depression.

Read the detailed description
  1. Dose range and administration mode: Oral Olanzapine 5mg - 20mg/day
  2. Duration:

    1. Screening phase is 2-28 days.
    2. Double-blind treatment phase is 6 weeks
    3. Open-label extension phase is 18 weeks
03

Conditions studied

  • Depression, Bipolar

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Each patient must be reliable, have a level of understanding sufficient to perform all tests and examinations required by the protocol, and must understand the nature of the study and have provided
  • All female patients must test negative for pregnancy and females of breast-feeding potential must agree not to breastfeed an infant during the study and for 1 month following the last dose of study drug
  • Patients must fulfill the criteria for a major depressive episode according to the , Fourth Edition (DSM-IV-TR) as well as criteria for bipolar I disorder, depressed, as defined in the DSM-IV-TR, based on clinical assessment and confirmed by the structured diagnostic interview, the Mini International Neuropsychiatric Interview (MINI), at study entry
  • Patients must have a current 17-item Hamilton Depression Rating Scale (HAMD-17) score greater than or equal to 18 at Visit 1 and Visit 2
  • Patients must have a current Young Mania Rating Scale (YMRS) total score less than or equal to 8 at Visit 2.

Exclusion criteria

Exclusion Criteria:

  • Has received treatment within the past 30 days with a drug (not including study drug) that has not received regulatory approval for any indication at the time of study entry
  • Has participated in a clinical trial of another drug, including olanzapine, within 1 month (30 days) before study entry
  • Was previously treated with olanzapine and had bipolar depression considered to be treatment-resistant to olanzapine or to olanzapine in combination with an available selective serotonin reuptake inhibitor (SSRI)
  • Is experiencing (at the time of study entry) a current episode of bipolar depression that is greater than 90 days in duration
  • Has been treatment-resistant to any therapy prescribed for bipolar depression when olanzapine alone or with an SSRI prescribed at an appropriate dose and duration
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
514 participants (actual)

Study arms

  • Experimental
    Olanzapine

    During double-blind treatment, participants receive olanzapine at a dose of 5 milligram (mg) which is increased to 10 mg per day no later than 3-7 days after randomization (Baseline). Subsequent dose increases above 10 mg (up to a maximum of 20 mg per day) are permitted in 5 mg per day increments, based upon tolerability and symptoms. Dosing may be decreased by any number of decrements, however dosing below 5 mg requires study discontinuation.

    Drug: Olanzapine

  • Placebo comparator
    Placebo

    Matching placebo administered once daily, by mouth during double-blind treatment.

    Drug: Placebo

  • Experimental
    Olanzapine (open-label treatment period)

    During open-label treatment, participants randomized to placebo in double-blind period will receive olanzapine 5 mg starting at Week 6. Participants randomized to olanzapine must be at a 5 mg olanzapine dose at Week 7. Those on higher doses will be reduced between Week 6 and Week 7 (10 mg reduced to 5 mg; 15 mg reduced to 10 mg and then to 5 mg at Week 7; 20 mg reduced to 15 mg and then 10 mg to dosing at 5 mg at Week 7). Dose increases beyond Week 7 are permitted and at the investigator's discretion.

    Drug: Olanzapine

Interventions

  • 5-20 mg, oral, once daily, for 24 weeks (participants randomized to olanzapine in double-blind treatment period) or 18 weeks (participants randomized to placebo in double-blind treatment period).

    Also known as: LY170053, Zyprexa

  • DrugPlacebo

    placebo tablets, oral, once daily at bedtime, 6 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score (Acute Phase)

    The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

    Time frame: Baseline, Endpoint (Week 6)

Secondary outcomes

  1. Percentage of Participants With Symptomatic Response at Endpoint (Acute Phase)

    Response is defined as a reduction (from baseline to endpoint) of 50% or more in the MADRS total score. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

    Time frame: Endpoint (Week 6)

  2. Percentage of Participants With Symptomatic Remission At Any Time (Acute Phase)

    Percentage of participants with symptomatic remission at any time as defined as a score of less than or equal to 12 in the MADRS total score. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

    Time frame: Baseline through Endpoint (Week 6)

  3. Change From Baseline to Endpoint in Clinical Global Improvement- Bipolar (CGI-BP) Severity of Illness Scores-Mania, Depression, Overall Bipolar Illness Scores (Acute Phase)

    CGI-BP is a measure of illness severity especially adapted for bipolar illness. It allows rating of mania, depression, and overall illness. The score ranges from 1 (normal, not ill) to 7 (very seriously ill).

    Time frame: Baseline, Endpoint (Week 6)

  4. Percentage of Participants With Recovery (Acute Phase)

    Percentage of participants with recovery defined as a value of less than or equal to 12 in the MADRS total score for at least 4 weeks of post-baseline treatment. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

    Time frame: Baseline through Endpoint (Week 6 )

  5. Change From Baseline to Endpoint in Young Mania Rating Scale (YMRS) Total Score (Acute Phase)

    The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

    Time frame: Baseline, Endpoint (Week 6)

  6. Change From Baseline to Endpoint in Hamilton Depression Rating Scale-17 (HAMD-17) Total Score (Acute Phase)

    The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).

    Time frame: Baseline, Endpoint (Week 6)

  7. Percentage of Participants With Major Depressive Episode at Endpoint on Mini International Neuropsychiatric Interview (MINI), Depressive Episode Module (Acute Phase)

    In the MINI Major Depressive Episode module, participants are asked a series of Yes/No questions to determine whether or not they are experiencing a major depressive episode or a major depressive episode with melancholic features.

    Time frame: Endpoint (Week 6)

  8. Percentage of Participants With Current Hypomanic Episode at Endpoint on MINI Manic Episode Module (Acute Phase)

    In the MINI Manic Episode module, participants are asked a series of Yes/No questions to determine whether or not they are currently experiencing hypomanic or manic episodes.

    Time frame: Endpoint (Week 6)

  9. Percentage of Participants With Psychotic Disorders and Mood Disorders With Psychotic Features at Endpoint on MINI Psychotic Disorders Module (Acute Phase)

    In the MINI Psychotic Features Episode module, participants are asked a series of Yes/No questions to determine whether or not they are currently experiencing mood disorder with psychotic features or current psychotic disorders.

    Time frame: Endpoint (Week 6)

  10. Percentage of Participants With Alcohol Dependence and Abuse at Endpoint on MINI Alcohol Dependence/Abuse Module (Acute Phase)

    In the MINI Alcohol Abuse and Dependence Module, participants are asked a series of Yes/No questions to determine whether or not they are currently experiencing symptoms indicating current alcohol dependence or abuse.

    Time frame: Endpoint (Week 6)

  11. Percentage of Participants With Non-Alcohol Psychoactive Substance Use Disorder at Endpoint on MINI Substance Dependence/Abuse Module (Acute Phase)

    In the MINI Substance Dependence and Abuse Module, participants are asked a series of Yes/No questions to determine whether or not they are currently experiencing symptoms indicating current non-alcohol substance use dependence or abuse.

    Time frame: Endpoint (Week 6)

  12. Percentage of Participants With Emergence of Mania During the Study (Acute Phase)

    Emergence of mania is defined as first occurrence of score of \>=15 in the YMRS total score in the post-baseline period of Acute Phase. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

    Time frame: Baseline through Endpoint (Week 6)

  13. Percentage of Participants With Extra-Pyramidal Symptoms (EPS) At Endpoint As Measured by Drug-Induced Extra-Pyramidal Symptoms Scale (DIEPSS) (Acute Phase)

    EPS symptoms measured by DIEPSS are grouped into 4 categories: parkinsonism, akathisia, dystonia, and dyskinesia. Severity is assessed at 5 levels, from level 0 (none, normal) to level 4 (severe). For Parkinsonism, normal baseline is defined as a score not \>=3 on 1 item nor \>=2 on 2 items; abnormal endpoint is defined as a score \>=3 on 1 item or \>=2 on 2 items, or an increase of 3 on Parkinsonism total. Baseline akathisia, dystonia and dyskinesia is defined as a score \<2; abnormal endpoint is a score \>=2 or an increase \>= 2 from that baseline score.

    Time frame: Endpoint (Week 6)

  14. Change From Baseline to Endpoint in Blood Pressure (Acute Phase)

    Time frame: Baseline, Endpoint (Week 6)

  15. Change From Baseline to Endpoint in Weight (Acute Phase)

    Time frame: Baseline, Endpoint (Week 6)

  16. Change From Baseline to Endpoint in Glucose and Lipids (Cholesterol, Triglycerides, HDL Cholesterol, LDL Cholesterol)

    Time frame: Baseline, Endpoint (Week 6)

  17. Change From Baseline to Endpoint in Albumin (Acute Phase)

    Time frame: Baseline, Endpoint (Week 6)

  18. Change From Baseline to Endpoint in Alanine Amino Transferase/Serum Glutamate Pyruvate Transaminase (ALT/SGPT), Aspartate Aminotransferase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT), Gamma Glutamyl Transferase (GGT)

    Time frame: Baseline, Endpoint (Week 6)

  19. Change From Baseline to Endpoint in Direct Bilirubin, Total Bilirubin, Uric Acid (Acute Phase)

    Time frame: Baseline, Endpoint (Week 6)

  20. Change From Baseline to Endpoint in Erythrocyte Count (Acute Phase)

    Time frame: Baseline, Endpoint (Week 6)

  21. Change From Baseline to Endpoint in Hematocrit (Acute Phase)

    Time frame: Baseline, Endpoint (Week 6)

  22. Change From Baseline to Endpoint in Hemoglobin A1c (Acute Phase)

    Time frame: Baseline, Endpoint (Week 6)

  23. Change From Baseline to Endpoint in Hemoglobin (Acute Phase)

    Time frame: Baseline, Endpoint (Week 6)

  24. Change From Baseline to Endpoint in Prolactin (Acute Phase)

    Time frame: Baseline, Endpoint (Week 6)

  25. Change From Baseline to Endpoint in Urinalysis (UA)- Specific Gravity (Acute Phase)

    Time frame: Baseline, Endpoint (Week 6)

  26. Change in Electrocardiogram (ECG) From Baseline to Endpoint (Acute Phase)

    Time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole, fixed correction factor (QTcF interval); Bazett-Corrected QT Interval (QTcB interval).

    Time frame: Baseline, Endpoint (Week 6)

  27. Change From Baseline to Endpoint in Heart Rate (Acute Phase)

    Time frame: Baseline, Endpoint (Week 6)

  28. Change From Baseline to Endpoint in MINI Suicidality Total Scores (Acute Phase)

    The MINI module C (MINI-C) is a rating scale for severity of suicidal thoughts and behaviors. The MINI-C is composed of 12 Yes/No questions with variable scores assigned to each question. The scale ranges from 0 to 52 with higher scores indicating a greater presence of suicidal thoughts and/or behaviors.

    Time frame: Baseline, Endpoint (Week 6)

  29. Number of Participants With Adverse Events (Acute Phase)

    Please refer to the Adverse Event overview for details regarding adverse events and serious adverse events.

    Time frame: Baseline through Week 6 (Acute Phase)

  30. Percentage of Participants With Symptomatic Response in Montgomery-Asberg Depression Rating (MADRS) Depression Rating (Open-Label Phase)

    The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Response is defined as a reduction (from baseline to endpoint) of 50% or more in the MADRS total score.

    Time frame: Baseline (End of Acute Phase/Week 6) through Endpoint (Week 24)

  31. Percentage of Participants With Symptomatic Remission in the MADRS Total Score (Open-Label Phase)

    Percentage of participants with symptomatic remission at any time as defined as a score of less than or equal to 12 in the MADRS total score. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

    Time frame: Baseline (End of Acute Phase/Week 6) through Endpoint (Week 24)

  32. Percentage of Participants With Recovery (Open-Label Phase)

    Percentage of participants with recovery defined as a value of less than or equal to 12 in the MADRS total score for at least 4 weeks of post-baseline treatment. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

    Time frame: Baseline (End of Acute Phase/Week 6) through Endpoint (Week 24)

  33. Change From Baseline to Endpoint in Young Mania Rating Scale (YMRS) Total Score (Open-Label Phase)

    The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

    Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)

  34. Percentage of Participants With Emergence of Mania During the Study (Open-Label Phase)

    Emergence of mania is defined as first occurrence of score of \>=15 in the YMRS total score in the Open-Label Extension. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

    Time frame: Baseline (End of Acute Phase/Week 6) through Endpoint (Week 24)

  35. Percentage of Participants With Extra-Pyramidal Symptoms (EPS) at Endpoint As Measured by Drug-Induced Extra-Pyramidal Symptoms Scale (DIEPSS) (Open-Label Phase)

    EPS symptoms measured by DIEPSS are grouped into 4 categories: parkinsonism, akathisia, dystonia, and dyskinesia. Severity is assessed at 5 levels, from level 0 (none, normal) to level 4 (severe). For Parkinsonism, normal baseline is defined as a score not \>=3 on 1 item nor \>=2 on 2 items; abnormal endpoint is defined as a score \>=3 on 1 item or \>=2 on 2 items, or an increase of 3 on Parkinsonism total. Baseline akathisia, dystonia and dyskinesia is defined as a score \<2; abnormal endpoint is a score \>=2 or an increase \>= 2 from that baseline score.

    Time frame: Endpoint (Week 24)

  36. Change From Baseline to Endpoint in Blood Pressure (Open-Label Phase)

    Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)

  37. Change From Baseline to Endpoint in Weight (Open-Label Phase)

    Time frame: Baseline (End of Acute Phase/ Week 6), Endpoint (Week 24)

  38. Change From Baseline to Endpoint in Albumin and Total Protein (Open-Label Phase)

    Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)

  39. Change From Baseline to Endpoint in Alkaline Phosphatase, Creatinine Phosphokinase (CPK), GGT (Open-Label Phase)

    Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)

  40. Change From Baseline to Endpoint in Chloride (Open-Label Phase)

    Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)

  41. Change From Baseline to Endpoint in Creatinine (Open-Label Phase)

    Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)

  42. Change From Baseline to Endpoint in Erythrocyte Count (Open-Label Phase)

    Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)

  43. Change From Baseline to Endpoint in Hemoglobin (Open-Label Phase)

    Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)

  44. Change From Baseline to Endpoint in Platelet Count (Open-Label Phase)

    Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)

  45. Change From Baseline to Endpoint in Prolactin (Open-Label Phase)

    Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)

  46. Change From Baseline to Endpoint in Uric Acid (Open-Label Phase)

    Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)

  47. Change From Baseline to Endpoint in Glucose and Lipids (Cholesterol, Triglycerides, HDL Cholesterol, LDL Cholesterol) (Open-Label Phase)

    Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)

  48. Change From Baseline to Endpoint in ECG (Open-Label Phase)

    Time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole, fixed correction factor (QTcF interval); Bazett-Corrected QT Interval (QTcB interval).

    Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)

  49. Change From Baseline to Endpoint in Heart Rate (Open-Label Phase)

    Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)

  50. Percentage of Participants With High Suicidality at Endpoint (Open-Label Phase)

    The MINI module C (MINI-C) is a rating scale for severity of suicidal thoughts and behaviors. The MINI-C is composed of 12 Yes/No questions with variable scores assigned to each question. The scale ranges from 0 to 52 with higher scores indicating a greater presence of suicidal thoughts and/or behaviors. Based upon scores, suicidality is defined as Low (1-8), Medium (9-16), and High (\>=17).

    Time frame: Endpoint (Week 24)

  51. Number of Participants With Adverse Events (Open-Label Phase)

    Please refer to the Adverse Event overview for details regarding adverse events and serious adverse events.

    Time frame: Baseline (End of Acute Phase/Week 6) through Endpoint (Week 24)

07

Results

Posted May 26, 2011

Participant flow

Double-Blind Treatment
Participant flow — Double-Blind Treatment
MilestoneOlanzapinePlacebo
Started343171
Completed267122
Not completed7649
Withdrew: Adverse event3013
Withdrew: Lack of efficacy613
Withdrew: Lost to follow-up37
Withdrew: Physician decision60
Withdrew: Protocol violation12
Withdrew: Withdrawal by subject2713
Withdrew: Clinical relapse01
Withdrew: Entry criteria not met30
Open-Label Treatment
Participant flow — Open-Label Treatment
MilestoneOlanzapinePlacebo
Started267122
Completed19696
Not completed7126
Withdrew: Adverse event228
Withdrew: Death11
Withdrew: Lack of efficacy40
Withdrew: Lost to follow-up101
Withdrew: Physician decision31
Withdrew: Protocol violation42
Withdrew: Withdrawal by subject2412
Withdrew: Clinical relapse11
Withdrew: Sponsor decision20

Outcome measures

PrimaryChange From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score (Acute Phase)

The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

Time frame:
Baseline, Endpoint (Week 6)
Reported as:
Mean · units on a scale
Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score (Acute Phase)
units on a scaleOlanzapinePlacebo
Baseline29.36 ± 5.7128.69 ± 6.33
Change-14.26 ± 9.73-11.71 ± 11.09
Statistical analysis
  • Olanzapine vs Placebo · ANCOVA · p = 0.018 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint in MADRS total score from the following ANCOVA model: Change=Treatment+Baseline+Geographic Region.) · Mean difference (final values): -2.15 · 95% CI -3.93 to -0.36
SecondaryPercentage of Participants With Symptomatic Response at Endpoint (Acute Phase)

Response is defined as a reduction (from baseline to endpoint) of 50% or more in the MADRS total score. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

Time frame:
Endpoint (Week 6)
Reported as:
Number · percentage of participants
Percentage of Participants With Symptomatic Response at Endpoint (Acute Phase)
percentage of participantsOlanzapinePlacebo
Percentage of Participants With Symptomatic Response at Endpoint (Acute Phase)52.543.3
Statistical analysis
  • Olanzapine vs Placebo · Cochran-Mantel-Haenszel · p = 0.050 (p-value represents a comparison of the olanzapine and placebo groups in percentage of participants with symptomatic response at endpoint from a Cochran-Mantel-Haenszel test using geographic region as strata.)
SecondaryPercentage of Participants With Symptomatic Remission At Any Time (Acute Phase)

Percentage of participants with symptomatic remission at any time as defined as a score of less than or equal to 12 in the MADRS total score. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

Time frame:
Baseline through Endpoint (Week 6)
Reported as:
Number · percentage of participants
Percentage of Participants With Symptomatic Remission At Any Time (Acute Phase)
percentage of participantsOlanzapinePlacebo
Percentage of Participants With Symptomatic Remission At Any Time (Acute Phase)53.949.7
Statistical analysis
  • Olanzapine vs Placebo · Cochran-Mantel-Haenszel · p = 0.367 (p-value represents a comparison of the olanzapine and placebo groups in percentage of participants with symptomatic remission at any time from a Cochran-Mantel-Haenszel test using region as strata.)
SecondaryChange From Baseline to Endpoint in Clinical Global Improvement- Bipolar (CGI-BP) Severity of Illness Scores-Mania, Depression, Overall Bipolar Illness Scores (Acute Phase)

CGI-BP is a measure of illness severity especially adapted for bipolar illness. It allows rating of mania, depression, and overall illness. The score ranges from 1 (normal, not ill) to 7 (very seriously ill).

Time frame:
Baseline, Endpoint (Week 6)
Reported as:
Mean · units on a scale
Change From Baseline to Endpoint in Clinical Global Improvement- Bipolar (CGI-BP) Severity of Illness Scores-Mania, Depression, Overall Bipolar Illness Scores (Acute Phase)
units on a scaleOlanzapinePlacebo
Baseline-Mania1.07 ± 0.291.11 ± 0.35
Change-Mania0.00 ± 0.430.09 ± 0.59
Baseline-Depression4.54 ± 0.734.53 ± 0.73
Change-Depression-1.45 ± 1.26-1.20 ± 1.36
Baseline- Overall4.45 ± 0.794.44 ± 0.79
Change- Overall-1.40 ± 1.28-1.08 ± 1.27
Statistical analysis
  • Olanzapine vs Placebo · ANCOVA · p = 0.008 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint in CGI-BP Mania score from the following ANCOVA model: Change=Treatment+Baseline+Geographic Region.) · Median difference (final values): -0.11 · 95% CI -0.20 to -0.03
  • Olanzapine vs Placebo · ANCOVA · p = 0.037 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint in CGI-BP Depression score from the following ANCOVA model: Change=Treatment+Baseline+Geographic Region.) · Median difference (final values): -0.24 · 95% CI -0.47 to -0.01
  • Olanzapine vs Placebo · ANCOVA · p = 0.008 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint in CGI-BP Overall score from the following ANCOVA model: Change=Treatment+Baseline+Geographic Region.) · Median difference (final values): -0.30 · 95% CI -0.53 to -0.08
SecondaryPercentage of Participants With Recovery (Acute Phase)

Percentage of participants with recovery defined as a value of less than or equal to 12 in the MADRS total score for at least 4 weeks of post-baseline treatment. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

Time frame:
Baseline through Endpoint (Week 6 )
Reported as:
Number · percentage of participants
Percentage of Participants With Recovery (Acute Phase)
percentage of participantsOlanzapinePlacebo
Percentage of Participants With Recovery (Acute Phase)13.79.4
Statistical analysis
  • Olanzapine vs Placebo · Cochran-Mantel-Haenszel · p = 0.156 (p-value represents a comparison of the olanzapine and placebo groups in percentage of participants with recovery from a Cochran-Mantel-Haenszel test using region as strata.)
SecondaryChange From Baseline to Endpoint in Young Mania Rating Scale (YMRS) Total Score (Acute Phase)

The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

Time frame:
Baseline, Endpoint (Week 6)
Reported as:
Mean · units on a scale
Change From Baseline to Endpoint in Young Mania Rating Scale (YMRS) Total Score (Acute Phase)
units on a scaleOlanzapinePlacebo
Baseline2.14 ± 2.101.95 ± 2.18
Change-0.78 ± 2.560.31 ± 4.21
Statistical analysis
  • Olanzapine vs Placebo · ANCOVA · p = <0.001 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint from the following ANCOVA model: Change=Treatment+Baseline+Geographic Region.) · Mean difference (final values): -0.99 · 95% CI -1.56 to -0.43
SecondaryChange From Baseline to Endpoint in Hamilton Depression Rating Scale-17 (HAMD-17) Total Score (Acute Phase)

The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).

Time frame:
Baseline, Endpoint (Week 6)
Reported as:
Mean · units on a scale
Change From Baseline to Endpoint in Hamilton Depression Rating Scale-17 (HAMD-17) Total Score (Acute Phase)
units on a scaleOlanzapinePlacebo
Baseline22.62 ± 3.4722.35 ± 3.53
Change-11.44 ± 7.02-9.12 ± 7.99
Statistical analysis
  • Olanzapine vs Placebo · ANCOVA · p = 0.002 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint from the following ANCOVA model: Change=Treatment+Baseline+Geographic Region.) · Mean difference (final values): -2.21 · 95% CI -3.61 to -0.81
SecondaryPercentage of Participants With Major Depressive Episode at Endpoint on Mini International Neuropsychiatric Interview (MINI), Depressive Episode Module (Acute Phase)

In the MINI Major Depressive Episode module, participants are asked a series of Yes/No questions to determine whether or not they are experiencing a major depressive episode or a major depressive episode with melancholic features.

Time frame:
Endpoint (Week 6)
Reported as:
Number · percentage of participants
Percentage of Participants With Major Depressive Episode at Endpoint on Mini International Neuropsychiatric Interview (MINI), Depressive Episode Module (Acute Phase)
percentage of participantsOlanzapinePlacebo
Major Depressive Episode55.560.4
Major Depressive Episode with Melancholic Features77.874.1
Statistical analysis
  • Olanzapine vs Placebo · Cochran-Mantel-Haenszel · p = 0.297 (p-value represents a comparison of the olanzapine and placebo groups in percentage of participants with major depressive episode from a Cochran-Mantel-Haenszel test using geographic region as strata.)
  • Olanzapine vs Placebo · Cochran-Mantel-Haenszel · p = 0.264 (p-value represents a comparison of the olanzapine and placebo groups in percentage of participants with major depressive episode with melancholic features from a Cochran-Mantel-Haenszel test using geographic region as strata.)
SecondaryPercentage of Participants With Current Hypomanic Episode at Endpoint on MINI Manic Episode Module (Acute Phase)

In the MINI Manic Episode module, participants are asked a series of Yes/No questions to determine whether or not they are currently experiencing hypomanic or manic episodes.

Time frame:
Endpoint (Week 6)
Reported as:
Number · percentage of participants
Percentage of Participants With Current Hypomanic Episode at Endpoint on MINI Manic Episode Module (Acute Phase)
percentage of participantsOlanzapinePlacebo
Percentage of Participants With Current Hypomanic Episode at Endpoint on MINI Manic Episode Module (Acute Phase)2.10.6
Statistical analysis
  • Olanzapine vs Placebo · Cochran-Mantel-Haenszel · p = 0.195 (p-value represents a comparison of the olanzapine and placebo groups in percentage of participants with current hypomanic episode from a Cochran-Mantel-Haenszel test using geographic region as strata.)
SecondaryPercentage of Participants With Psychotic Disorders and Mood Disorders With Psychotic Features at Endpoint on MINI Psychotic Disorders Module (Acute Phase)

In the MINI Psychotic Features Episode module, participants are asked a series of Yes/No questions to determine whether or not they are currently experiencing mood disorder with psychotic features or current psychotic disorders.

Time frame:
Endpoint (Week 6)
Reported as:
Number · percentage of participants
Percentage of Participants With Psychotic Disorders and Mood Disorders With Psychotic Features at Endpoint on MINI Psychotic Disorders Module (Acute Phase)
percentage of participantsOlanzapinePlacebo
Mood Disorder with Psychotic Features3.62.4
Psychotic Disorders0.00.6
Statistical analysis
  • Olanzapine vs Placebo · Cochran-Mantel-Haenszel · p = 0.163 (p-value represents a comparison of the olanzapine and placebo groups in percentage of participants with current psychotic disorders from a Cochran-Mantel-Haenszel test using geographic region as strata.)
  • Olanzapine vs Placebo · Cochran-Mantel-Haenszel · p = 0.442 (p-value represents a comparison of the olanzapine and placebo groups in percentage of participants with current mood disorders with psychotic features from a Cochran-Mantel-Haenszel test using geographic region as strata.)
SecondaryPercentage of Participants With Alcohol Dependence and Abuse at Endpoint on MINI Alcohol Dependence/Abuse Module (Acute Phase)

In the MINI Alcohol Abuse and Dependence Module, participants are asked a series of Yes/No questions to determine whether or not they are currently experiencing symptoms indicating current alcohol dependence or abuse.

Time frame:
Endpoint (Week 6)
Reported as:
Number · percentage of participants
Percentage of Participants With Alcohol Dependence and Abuse at Endpoint on MINI Alcohol Dependence/Abuse Module (Acute Phase)
percentage of participantsOlanzapinePlacebo
Dependence0.60.6
Abuse0.60.0
Statistical analysis
  • Olanzapine vs Placebo · Cochran-Mantel-Haenszel · p = 1.00 (p-value represents a comparison of the olanzapine and placebo groups in percentage of participants with current alcohol dependence from a Cochran-Mantel-Haenszel test using geographic region as strata.)
  • Olanzapine vs Placebo · Cochran-Mantel-Haenszel · p = 0.324 (p-value represents a comparison of the olanzapine and placebo groups in percentage of participants with current alcohol abuse from a Cochran-Mantel-Haenszel test using geographic region as strata.)
SecondaryPercentage of Participants With Non-Alcohol Psychoactive Substance Use Disorder at Endpoint on MINI Substance Dependence/Abuse Module (Acute Phase)

In the MINI Substance Dependence and Abuse Module, participants are asked a series of Yes/No questions to determine whether or not they are currently experiencing symptoms indicating current non-alcohol substance use dependence or abuse.

Time frame:
Endpoint (Week 6)
Reported as:
Number · percentage of participants
Percentage of Participants With Non-Alcohol Psychoactive Substance Use Disorder at Endpoint on MINI Substance Dependence/Abuse Module (Acute Phase)
percentage of participantsOlanzapinePlacebo
Dependence0.00.0
Abuse0.00.0
SecondaryPercentage of Participants With Emergence of Mania During the Study (Acute Phase)

Emergence of mania is defined as first occurrence of score of \>=15 in the YMRS total score in the post-baseline period of Acute Phase. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

Time frame:
Baseline through Endpoint (Week 6)
Reported as:
Number · percentage of participants
Percentage of Participants With Emergence of Mania During the Study (Acute Phase)
percentage of participantsOlanzapinePlacebo
Percentage of Participants With Emergence of Mania During the Study (Acute Phase)0.62.9
Statistical analysis
  • Olanzapine vs Placebo · Cochran-Mantel-Haenszel · p = 0.031 (p-value represents a comparison of the olanzapine and placebo groups in percentage of participants with emergence of mania at endpoint from a Cochran-Mantel-Haenszel test using geographic region as strata.)
SecondaryPercentage of Participants With Extra-Pyramidal Symptoms (EPS) At Endpoint As Measured by Drug-Induced Extra-Pyramidal Symptoms Scale (DIEPSS) (Acute Phase)

EPS symptoms measured by DIEPSS are grouped into 4 categories: parkinsonism, akathisia, dystonia, and dyskinesia. Severity is assessed at 5 levels, from level 0 (none, normal) to level 4 (severe). For Parkinsonism, normal baseline is defined as a score not \>=3 on 1 item nor \>=2 on 2 items; abnormal endpoint is defined as a score \>=3 on 1 item or \>=2 on 2 items, or an increase of 3 on Parkinsonism total. Baseline akathisia, dystonia and dyskinesia is defined as a score \<2; abnormal endpoint is a score \>=2 or an increase \>= 2 from that baseline score.

Time frame:
Endpoint (Week 6)
Reported as:
Number · percentage of participants
Percentage of Participants With Extra-Pyramidal Symptoms (EPS) At Endpoint As Measured by Drug-Induced Extra-Pyramidal Symptoms Scale (DIEPSS) (Acute Phase)
percentage of participantsOlanzapinePlacebo
Akathisia (N=335, 169)2.71.2
Dyskinesia (N=337, 169)0.00.0
Dystonia (N=337, 169)0.00.0
Parkinsonism (N=337, 169)0.90.6
Statistical analysis
  • Olanzapine vs Placebo · Cochran-Mantel-Haenszel · p = 0.269 (p-value represents a comparison of the olanzapine and placebo groups in percentage of participants with EPS symptoms (akathisia) at endpoint from a Cochran-Mantel-Haenszel test using geographic region as strata.)
  • Olanzapine vs Placebo · Cochran-Mantel-Haenszel · p = 0.736 (p-value represents a comparison of the olanzapine and placebo groups in percentage of participants with EPS symptoms (parkinsonism) at endpoint from a Cochran-Mantel-Haenszel test using geographic region as strata.)
SecondaryChange From Baseline to Endpoint in Blood Pressure (Acute Phase)
Time frame:
Baseline, Endpoint (Week 6)
Reported as:
Mean · mmHg (millimeters of mercury)
Change From Baseline to Endpoint in Blood Pressure (Acute Phase)
mmHg (millimeters of mercury)OlanzapinePlacebo
Baseline- Standing Systolic (N=320, 159)112.39 ± 13.25115.65 ± 14.39
Change- Standing Systolic (N=320, 159)-0.99 ± 10.83-0.67 ± 11.18
Baseline- Sitting Systolic (N=340, 169)112.35 ± 13.42114.39 ± 13.67
Change- Sitting Systolic (N=340, 169)-0.36 ± 11.100.04 ± 12.16
Baseline- Standing Diastolic (N=320, 159)74.77 ± 10.2076.87 ± 10.26
Change- Standing Diastolic (N=320, 159)-0.48 ± 8.71-0.14 ± 8.44
Baseline- Sitting Diastolic (N=340, 169)73.07 ± 9.9373.92 ± 9.86
Change- Sitting Diastolic (N=340, 169)-0.11 ± 9.370.39 ± 9.08
Baseline- Orthostatic Change-Systolic (N=320, 159)0.54 ± 6.511.21 ± 7.67
Change- Orthostatic Change-Systolic (N=320, 159)-0.65 ± 8.20-0.45 ± 11.45
Baseline- Orthostatic Change-Diastolic (N=320, 1591.92 ± 5.932.96 ± 5.57
Change- Orthostatic Change-Diastolic (N=320, 159)-0.52 ± 6.79-0.47 ± 6.78
Statistical analysis
  • Olanzapine vs Placebo · ANCOVA · p = 0.146 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint-standing systolic blood pressure from the following ANCOVA model: Change=Treatment+Baseline+Geographic Region.)
  • Olanzapine vs Placebo · ANCOVA · p = 0.249 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint-sitting systolic blood pressure from the following ANCOVA model: Change=Treatment+Baseline+Geographic Region.)
  • Olanzapine vs Placebo · ANCOVA · p = 0.146 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint-standing diastolic blood pressure from the following ANCOVA model: Change=Treatment+Baseline+Geographic Region.)
  • Olanzapine vs Placebo · ANCOVA · p = 0.271 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint-sitting diastolic blood pressure from the following ANCOVA model: Change=Treatment+Baseline+Geographic Region.)
  • Olanzapine vs Placebo · ANCOVA · p = 0.284 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint-orthostatic change in systolic blood pressure from the following ANCOVA model: Change=Treatment+Baseline+Geographic Region.)
  • Olanzapine vs Placebo · ANCOVA · p = 0.067 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint-orthostatic change in diastolic blood pressure from the following ANCOVA model: Change=Treatment+Baseline+Geographic Region.)
SecondaryChange From Baseline to Endpoint in Weight (Acute Phase)
Time frame:
Baseline, Endpoint (Week 6)
Reported as:
Mean · kilograms
Change From Baseline to Endpoint in Weight (Acute Phase)
kilogramsOlanzapinePlacebo
Baseline66.11 ± 18.1168.30 ± 18.73
Endpoint2.45 ± 2.82-0.13 ± 2.10
Statistical analysis
  • Olanzapine vs Placebo · ANCOVA · p = <0.001 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint-in weight from the following ANCOVA model: Change=Treatment+Baseline+Geographic Region.)
SecondaryChange From Baseline to Endpoint in Glucose and Lipids (Cholesterol, Triglycerides, HDL Cholesterol, LDL Cholesterol)
Time frame:
Baseline, Endpoint (Week 6)
Reported as:
Mean · millimole/Liter
Change From Baseline to Endpoint in Glucose and Lipids (Cholesterol, Triglycerides, HDL Cholesterol, LDL Cholesterol)
millimole/LiterOlanzapinePlacebo
Baseline- Fasting Glucose (N=320, 155)5.11 ± 0.585.12 ± 0.57
Change- Fasting Glucose (N=320, 155)0.10 ± 0.610.02 ± 0.54
Baseline- Cholesterol (N=329, 160)4.83 ± 1.014.81 ± 1.00
Change- Cholesterol (N=329, 160)0.24 ± 0.76-0.07 ± 0.49
Baseline-Triglycerides (N=329, 160)1.39 ± 0.851.34 ± 0.80
Change- Triglycerides (N=329, 160)0.26 ± 0.970.03 ± 0.71
Baseline- LDL Cholesterol (N=328, 159)2.77 ± 0.872.83 ± 0.84
Change- LDL Cholesterol (N=328, 159)0.17 ± 0.66-0.09 ± 0.48
Baseline- HDL Cholesterol (N=329, 160)1.43 ± 0.411.36 ± 0.35
Change- HDL Cholesterol (N=329, 160)-0.03 ± 0.250.02 ± 0.21
Statistical analysis
  • Olanzapine vs Placebo · ANCOVA · p = 0.179 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint-in fasting glucose from the following ANCOVA model: Change=Treatment+Baseline+Geographic Region.)
  • Olanzapine vs Placebo · ANCOVA · p = <0.001 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint-in cholesterol from the following ANCOVA model: Change=Treatment+Baseline+Geographic Region.)
  • Olanzapine vs Placebo · ANCOVA · p = 0.003 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint-in triglycerides from the following ANCOVA model: Change=Treatment+Baseline+Geographic Region.)
  • Olanzapine vs Placebo · ANCOVA · p = <0.001 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint-in LDL cholesterol from the following ANCOVA model: Change=Treatment+Baseline+Geographic Region.)
  • Olanzapine vs Placebo · ANCOVA · p = 0.095 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint-in HDL cholesterol from the following ANCOVA model: Change=Treatment+Baseline+Geographic Region.)
SecondaryChange From Baseline to Endpoint in Albumin (Acute Phase)
Time frame:
Baseline, Endpoint (Week 6)
Reported as:
Mean · gram/Liter
Change From Baseline to Endpoint in Albumin (Acute Phase)
gram/LiterOlanzapinePlacebo
Baseline43.07 ± 3.8543.47 ± 3.69
Change-0.81 ± 2.890.03 ± 3.11
Statistical analysis
  • Olanzapine vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.001 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint in albumin from Wilcoxon's rank-sum test.)
SecondaryChange From Baseline to Endpoint in Alanine Amino Transferase/Serum Glutamate Pyruvate Transaminase (ALT/SGPT), Aspartate Aminotransferase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT), Gamma Glutamyl Transferase (GGT)
Time frame:
Baseline, Endpoint (Week 6)
Reported as:
Mean · units/Liter
Change From Baseline to Endpoint in Alanine Amino Transferase/Serum Glutamate Pyruvate Transaminase (ALT/SGPT), Aspartate Aminotransferase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT), Gamma Glutamyl Transferase (GGT)
units/LiterOlanzapinePlacebo
Baseline (ALT/SGPT)21.68 ± 16.5321.18 ± 13.17
Change (ALT/SGPT)8.34 ± 26.900.00 ± 13.63
Baseline (AST/SGOT)21.61 ± 8.3420.25 ± 6.70
Change (AST/SGOT)4.31 ± 15.661.26 ± 11.06
Baseline (GGT)24.87 ± 36.5923.63 ± 23.17
Change (GGT)5.36 ± 22.70-1.21 ± 11.67
Statistical analysis
  • Olanzapine vs Placebo · Wilcoxon (Mann-Whitney) · p = <0.001 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint in ALT/SGPT from Wilcoxon's rank-sum test.)
  • Olanzapine vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.001 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint in AST/SGOT from Wilcoxon's rank-sum test.)
  • Olanzapine vs Placebo · Wilcoxon (Mann-Whitney) · p = <0.001 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint in GGT from Wilcoxon's rank-sum test.)
SecondaryChange From Baseline to Endpoint in Direct Bilirubin, Total Bilirubin, Uric Acid (Acute Phase)
Time frame:
Baseline, Endpoint (Week 6)
Reported as:
Mean · micromole/Liter
Change From Baseline to Endpoint in Direct Bilirubin, Total Bilirubin, Uric Acid (Acute Phase)
micromole/LiterOlanzapinePlacebo
Baseline- Direct Bilirubin2.45 ± 1.232.40 ± 1.08
Change- Direct Bilirubin-0.21 ± 1.030.12 ± 1.02
Baseline- Total Bilirubin9.74 ± 5.189.42 ± 4.58
Change- Total Bilirubin-0.68 ± 4.570.47 ± 4.27
Baseline- Uric Acid307.19 ± 92.03314.38 ± 86.69
Change- Uric Acid19.55 ± 51.10-1.86 ± 50.37
Statistical analysis
  • Olanzapine vs Placebo · Wilcoxon (Mann-Whitney) · p = <0.001 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint in direct bilirubin from Wilcoxon's rank-sum test.)
  • Olanzapine vs Placebo · Wilcoxon (Mann-Whitney) · p = <0.001 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint in total bilirubin from Wilcoxon's rank-sum test.)
  • Olanzapine vs Placebo · Wilcoxon (Mann-Whitney) · p = <0.001 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint in uric acid from Wilcoxon's rank-sum test.)
SecondaryChange From Baseline to Endpoint in Erythrocyte Count (Acute Phase)
Time frame:
Baseline, Endpoint (Week 6)
Reported as:
Mean · trillion cells per liter ( TRIL/L)
Change From Baseline to Endpoint in Erythrocyte Count (Acute Phase)
trillion cells per liter ( TRIL/L)OlanzapinePlacebo
Baseline4.65 ± 0.514.71 ± 0.52
Change-0.05 ± 0.270.02 ± 0.27
Statistical analysis
  • Olanzapine vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.003 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint in erythrocyte count from Wilcoxon's rank-sum test.)
SecondaryChange From Baseline to Endpoint in Hematocrit (Acute Phase)
Time frame:
Baseline, Endpoint (Week 6)
Reported as:
Mean · proportion of blood volume
Change From Baseline to Endpoint in Hematocrit (Acute Phase)
proportion of blood volumeOlanzapinePlacebo
Baseline0.42 ± 0.040.43 ± 0.05
Change-0.01 ± 0.030.00 ± 0.03
Statistical analysis
  • Olanzapine vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.001 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint in hematocrit from Wilcoxon's rank-sum test.)
SecondaryChange From Baseline to Endpoint in Hemoglobin A1c (Acute Phase)
Time frame:
Baseline, Endpoint (Week 6)
Reported as:
Mean · percent of glycosylated hemoglobin
Change From Baseline to Endpoint in Hemoglobin A1c (Acute Phase)
percent of glycosylated hemoglobinOlanzapinePlacebo
Baseline5.34 ± 0.375.37 ± 0.37
Change0.04 ± 0.26-0.03 ± 0.28
Statistical analysis
  • Olanzapine vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.009 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint in hemoglobin A1c from Wilcoxon's rank-sum test.)
SecondaryChange From Baseline to Endpoint in Hemoglobin (Acute Phase)
Time frame:
Baseline, Endpoint (Week 6)
Reported as:
Mean · millimole/Liter of iron (Fe)
Change From Baseline to Endpoint in Hemoglobin (Acute Phase)
millimole/Liter of iron (Fe)OlanzapinePlacebo
Baseline8.65 ± 0.998.73 ± 0.97
Change-0.11 ± 0.500.05 ± 0.50
Statistical analysis
  • Olanzapine vs Placebo · Wilcoxon (Mann-Whitney) · p = <0.001 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint in hemoglobin from Wilcoxon's rank-sum test.)
SecondaryChange From Baseline to Endpoint in Prolactin (Acute Phase)
Time frame:
Baseline, Endpoint (Week 6)
Reported as:
Mean · microgram/Liter
Change From Baseline to Endpoint in Prolactin (Acute Phase)
microgram/LiterOlanzapinePlacebo
Baseline15.40 ± 16.8915.86 ± 21.54
Change12.07 ± 24.00-1.18 ± 26.49
Statistical analysis
  • Olanzapine vs Placebo · Wilcoxon (Mann-Whitney) · p = <0.001 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint in prolactin from Wilcoxon's rank-sum test.)
SecondaryChange From Baseline to Endpoint in Urinalysis (UA)- Specific Gravity (Acute Phase)
Time frame:
Baseline, Endpoint (Week 6)
Reported as:
Mean · ratio
Change From Baseline to Endpoint in Urinalysis (UA)- Specific Gravity (Acute Phase)
ratioOlanzapinePlacebo
Baseline1.02 ± 0.011.02 ± 0.01
Change-0.00 ± 0.010.00 ± 0.01
Statistical analysis
  • Olanzapine vs Placebo · Wilcoxon (Mann-Whitney) · p = <0.001 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint in urinalysis-specific gravity from Wilcoxon's rank-sum test.)
SecondaryChange in Electrocardiogram (ECG) From Baseline to Endpoint (Acute Phase)

Time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole, fixed correction factor (QTcF interval); Bazett-Corrected QT Interval (QTcB interval).

Time frame:
Baseline, Endpoint (Week 6)
Reported as:
Mean · milliseconds
Change in Electrocardiogram (ECG) From Baseline to Endpoint (Acute Phase)
millisecondsOlanzapinePlacebo
Baseline- QTcF406.85 ± 19.53408.10 ± 18.72
Change- QTcF2.82 ± 14.210.50 ± 12.27
Baseline- QTcB415.79 ± 20.55418.42 ± 19.95
Change- QTcB6.58 ± 18.011.21 ± 16.02
Statistical analysis
  • Olanzapine vs Placebo · ANCOVA · p = 0.104 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint in QTcF interval from the following ANCOVA model: Change=Treatment+Baseline+Geographic Region.)
  • Olanzapine vs Placebo · ANCOVA · p = 0.006 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint in QTcB interval from the following ANCOVA model: Change=Treatment+Baseline+Geographic Region.)
SecondaryChange From Baseline to Endpoint in Heart Rate (Acute Phase)
Time frame:
Baseline, Endpoint (Week 6)
Reported as:
Mean · beats per minute (bpm)
Change From Baseline to Endpoint in Heart Rate (Acute Phase)
beats per minute (bpm)OlanzapinePlacebo
Baseline69.63 ± 12.6570.51 ± 11.94
Change3.49 ± 11.180.87 ± 11.51
Statistical analysis
  • Olanzapine vs Placebo · ANCOVA · p = 0.035 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint in heart rate from the following ANCOVA model: Change=Treatment+Baseline+Geographic Region.)
SecondaryChange From Baseline to Endpoint in MINI Suicidality Total Scores (Acute Phase)

The MINI module C (MINI-C) is a rating scale for severity of suicidal thoughts and behaviors. The MINI-C is composed of 12 Yes/No questions with variable scores assigned to each question. The scale ranges from 0 to 52 with higher scores indicating a greater presence of suicidal thoughts and/or behaviors.

Time frame:
Baseline, Endpoint (Week 6)
Reported as:
Mean · units on a scale
Change From Baseline to Endpoint in MINI Suicidality Total Scores (Acute Phase)
units on a scaleOlanzapinePlacebo
Baseline2.09 ± 3.442.40 ± 3.49
Change-0.42 ± 3.71-0.59 ± 3.44
Statistical analysis
  • Olanzapine vs Placebo · ANCOVA · p = 0.943 (p-value represents a comparison of the olanzapine and placebo groups in change from baseline to endpoint for MINI Suicidality Total Score from the following ANCOVA model: Change=Treatment+Baseline+Geographic Region.) · Mean difference (final values): 0.02 · 95% CI -0.59 to 0.64
SecondaryNumber of Participants With Adverse Events (Acute Phase)

Please refer to the Adverse Event overview for details regarding adverse events and serious adverse events.

Time frame:
Baseline through Week 6 (Acute Phase)
Reported as:
Number · participants
Number of Participants With Adverse Events (Acute Phase)
participantsOlanzapinePlacebo
Serious67
Non-Serious23888
SecondaryPercentage of Participants With Symptomatic Response in Montgomery-Asberg Depression Rating (MADRS) Depression Rating (Open-Label Phase)

The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Response is defined as a reduction (from baseline to endpoint) of 50% or more in the MADRS total score.

Time frame:
Baseline (End of Acute Phase/Week 6) through Endpoint (Week 24)
Reported as:
Number · percentage of participants
Percentage of Participants With Symptomatic Response in Montgomery-Asberg Depression Rating (MADRS) Depression Rating (Open-Label Phase)
percentage of participantsOlanzapine (Open-label Treatment Period)
Percentage of Participants With Symptomatic Response in Montgomery-Asberg Depression Rating (MADRS) Depression Rating (Open-Label Phase)43.7
SecondaryPercentage of Participants With Symptomatic Remission in the MADRS Total Score (Open-Label Phase)

Percentage of participants with symptomatic remission at any time as defined as a score of less than or equal to 12 in the MADRS total score. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

Time frame:
Baseline (End of Acute Phase/Week 6) through Endpoint (Week 24)
Reported as:
Number · percentage of participants
Percentage of Participants With Symptomatic Remission in the MADRS Total Score (Open-Label Phase)
percentage of participantsOlanzapine (Open-label Treatment Period)
Percentage of Participants With Symptomatic Remission in the MADRS Total Score (Open-Label Phase)85.1
SecondaryPercentage of Participants With Recovery (Open-Label Phase)

Percentage of participants with recovery defined as a value of less than or equal to 12 in the MADRS total score for at least 4 weeks of post-baseline treatment. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

Time frame:
Baseline (End of Acute Phase/Week 6) through Endpoint (Week 24)
Reported as:
Number · percentage of participants
Percentage of Participants With Recovery (Open-Label Phase)
percentage of participantsOlanzapine (Open-label Treatment Period)
Percentage of Participants With Recovery (Open-Label Phase)69.9
SecondaryChange From Baseline to Endpoint in Young Mania Rating Scale (YMRS) Total Score (Open-Label Phase)

The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

Time frame:
Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Reported as:
Mean · units on a scale
Change From Baseline to Endpoint in Young Mania Rating Scale (YMRS) Total Score (Open-Label Phase)
units on a scaleOlanzapine (Open-label Treatment Period)
Baseline1.11 ± 2.87
Change-0.03 ± 2.55
SecondaryPercentage of Participants With Emergence of Mania During the Study (Open-Label Phase)

Emergence of mania is defined as first occurrence of score of \>=15 in the YMRS total score in the Open-Label Extension. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

Time frame:
Baseline (End of Acute Phase/Week 6) through Endpoint (Week 24)
Reported as:
Number · percentage of participants
Percentage of Participants With Emergence of Mania During the Study (Open-Label Phase)
percentage of participantsOlanzapine (Open-label Treatment Period)
Percentage of Participants With Emergence of Mania During the Study (Open-Label Phase)0.8
SecondaryPercentage of Participants With Extra-Pyramidal Symptoms (EPS) at Endpoint As Measured by Drug-Induced Extra-Pyramidal Symptoms Scale (DIEPSS) (Open-Label Phase)

EPS symptoms measured by DIEPSS are grouped into 4 categories: parkinsonism, akathisia, dystonia, and dyskinesia. Severity is assessed at 5 levels, from level 0 (none, normal) to level 4 (severe). For Parkinsonism, normal baseline is defined as a score not \>=3 on 1 item nor \>=2 on 2 items; abnormal endpoint is defined as a score \>=3 on 1 item or \>=2 on 2 items, or an increase of 3 on Parkinsonism total. Baseline akathisia, dystonia and dyskinesia is defined as a score \<2; abnormal endpoint is a score \>=2 or an increase \>= 2 from that baseline score.

Time frame:
Endpoint (Week 24)
Reported as:
Number · percentage of participants
Percentage of Participants With Extra-Pyramidal Symptoms (EPS) at Endpoint As Measured by Drug-Induced Extra-Pyramidal Symptoms Scale (DIEPSS) (Open-Label Phase)
percentage of participantsOlanzapine (Open-label Treatment Period)
Akathisia (N=378)0.8
Dyskinesia (N=385)0.3
Dystonia (N=385)0.0
Parkinsonism (N=385)1.0
SecondaryChange From Baseline to Endpoint in Blood Pressure (Open-Label Phase)
Time frame:
Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Reported as:
Mean · millimeters of mercury
Change From Baseline to Endpoint in Blood Pressure (Open-Label Phase)
millimeters of mercuryOlanzapine (Open-label Treatment Period)
Baseline-Standing Diastolic (N=361)74.98 ± 10.77
Change- Standing Diastolic (N=361)0.15 ± 8.28
Baseline- Sitting Diastolic (N=383)73.32 ± 10.73
Change- Sitting Diastolic (N=383)-0.03 ± 8.68
Baseline- Standing Systolic (N=361)112.06 ± 14.58
Change- Standing Systolic (N=361)0.96 ± 10.37
Baseline- Sitting Systolic (N=383)112.26 ± 14.45
Change- Sitting Systolic (N=383)0.27 ± 10.28
Baseline- Orthostatic Change-Diastolic (N=358)1.75 ± 5.25
Change- Orthostatic Change- Diastolic (N=358)0.16 ± 6.56
Baseline- Orthostatic Change- Systolic (N=358)0.19 ± 6.19
Change- Orthostatic Change- Systolic (N=358)0.65 ± 7.92
Statistical analysis
  • Olanzapine (Open-label Treatment Period) · t-test, 2 sided · p = 0.736 (p-value represents change from baseline to endpoint-standing diastolic blood pressure from t-tests on change.)
  • Olanzapine (Open-label Treatment Period) · t-test, 2 sided · p = 0.944 (p-value represents change from baseline to endpoint-sitting diastolic blood pressure from t-tests on change.)
  • Olanzapine (Open-label Treatment Period) · t-test, 2 sided · p = 0.080 (p-value represents change from baseline to endpoint-standing systolic blood pressure from t-tests on change.)
  • Olanzapine (Open-label Treatment Period) · t-test, 2 sided · p = 0.612 (p-value represents change from baseline to endpoint-sitting systolic blood pressure from t-tests on change.)
  • Olanzapine (Open-label Treatment Period) · t-test, 2 sided · p = 0.640 (p-value represents change from baseline to endpoint-orthostatic change in diastolic blood pressure from t-tests on change.)
  • Olanzapine (Open-label Treatment Period) · t-test, 2 sided · p = 0.122 (p-value represents change from baseline to endpoint-orthostatic change in systolic blood pressure from t-tests on change.)
SecondaryChange From Baseline to Endpoint in Weight (Open-Label Phase)
Time frame:
Baseline (End of Acute Phase/ Week 6), Endpoint (Week 24)
Reported as:
Mean · kilograms
Change From Baseline to Endpoint in Weight (Open-Label Phase)
kilogramsOlanzapine (Open-label Treatment Period)
Baseline68.31 ± 18.54
Change2.27 ± 4.00
Statistical analysis
  • Olanzapine (Open-label Treatment Period) · t-test, 2 sided · p = <0.001 (p-value represents change from baseline to endpoint for weight from t-tests on change.)
SecondaryChange From Baseline to Endpoint in Albumin and Total Protein (Open-Label Phase)
Time frame:
Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Reported as:
Mean · gram/Liter
Change From Baseline to Endpoint in Albumin and Total Protein (Open-Label Phase)
gram/LiterOlanzapine (Open-label Treatment Period)
Baseline- Albumin42.64 ± 3.58
Change- Albumin0.53 ± 2.86
Baseline- Total Protein73.24 ± 4.39
Change- Total Protein0.56 ± 3.78
Statistical analysis
  • Olanzapine (Open-label Treatment Period) · Wilcoxon (Mann-Whitney) · p = <0.001 (p-value represents change from baseline to endpoint for albumin from Wilcoxon's signed-rank test.)
  • Olanzapine (Open-label Treatment Period) · Wilcoxon (Mann-Whitney) · p = 0.002 (p-value represents change from baseline to endpoint for total protein from Wilcoxon's signed-rank test.)
SecondaryChange From Baseline to Endpoint in Alkaline Phosphatase, Creatinine Phosphokinase (CPK), GGT (Open-Label Phase)
Time frame:
Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Reported as:
Mean · units/Liter
Change From Baseline to Endpoint in Alkaline Phosphatase, Creatinine Phosphokinase (CPK), GGT (Open-Label Phase)
units/LiterOlanzapine (Open-label Treatment Period)
Baseline- Alkaline Phosphatase68.58 ± 19.33
Change- Alkaline Phosphatase2.37 ± 12.85
Baseline- CPK107.36 ± 133.21
Change- CPK-1.73 ± 124.56
Baseline- GGT28.90 ± 32.08
Change- GGT0.78 ± 25.90
Statistical analysis
  • Olanzapine (Open-label Treatment Period) · Wilcoxon (Mann-Whitney) · p = 0.002 (p-value represents change from baseline to endpoint for alkaline phosphatase from Wilcoxon's signed-rank test.)
  • Olanzapine (Open-label Treatment Period) · Wilcoxon (Mann-Whitney) · p = 0.010 (p-value represents change from baseline to endpoint for CPK from Wilcoxon's signed-rank test.)
  • Olanzapine (Open-label Treatment Period) · Wilcoxon (Mann-Whitney) · p = 0.354 (p-value represents change from baseline to endpoint for GGT from Wilcoxon's signed-rank test.)
SecondaryChange From Baseline to Endpoint in Chloride (Open-Label Phase)
Time frame:
Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Reported as:
Mean · millimole/Liter
Change From Baseline to Endpoint in Chloride (Open-Label Phase)
millimole/LiterOlanzapine (Open-label Treatment Period)
Baseline103.62 ± 2.16
Change0.33 ± 2.38
Statistical analysis
  • Olanzapine (Open-label Treatment Period) · Wilcoxon (Mann-Whitney) · p = 0.010 (p-value represents change from baseline to endpoint for chlorine from Wilcoxon's signed-rank test.)
SecondaryChange From Baseline to Endpoint in Creatinine (Open-Label Phase)
Time frame:
Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Reported as:
Mean · micromole/Liter
Change From Baseline to Endpoint in Creatinine (Open-Label Phase)
micromole/LiterOlanzapine (Open-label Treatment Period)
Baseline67.48 ± 14.98
Change2.05 ± 7.90
Statistical analysis
  • Olanzapine (Open-label Treatment Period) · Wilcoxon (Mann-Whitney) · p = <0.001 (p-value represents change from baseline to endpoint for creatinine from Wilcoxon's signed-rank test.)
SecondaryChange From Baseline to Endpoint in Erythrocyte Count (Open-Label Phase)
Time frame:
Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Reported as:
Mean · trillion cells per liter (Tril/L)
Change From Baseline to Endpoint in Erythrocyte Count (Open-Label Phase)
trillion cells per liter (Tril/L)Olanzapine (Open-label Treatment Period)
Baseline4.64 ± 0.53
Change0.03 ± 0.30
Statistical analysis
  • Olanzapine (Open-label Treatment Period) · Wilcoxon (Mann-Whitney) · p = 0.021 (p-value represents change from baseline to endpoint for erythrocyte count from Wilcoxon's signed-rank test.)
SecondaryChange From Baseline to Endpoint in Hemoglobin (Open-Label Phase)
Time frame:
Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Reported as:
Mean · millimole/Liter of iron (Fe)
Change From Baseline to Endpoint in Hemoglobin (Open-Label Phase)
millimole/Liter of iron (Fe)Olanzapine (Open-label Treatment Period)
Baseline8.61 ± 1.01
Change0.04 ± 0.51
Statistical analysis
  • Olanzapine (Open-label Treatment Period) · Wilcoxon (Mann-Whitney) · p = 0.035 (p-value represents change from baseline to endpoint for hemoglobin from Wilcoxon's signed-rank test.)
SecondaryChange From Baseline to Endpoint in Platelet Count (Open-Label Phase)
Time frame:
Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Reported as:
Mean · billion cells per liter (BILL/L)
Change From Baseline to Endpoint in Platelet Count (Open-Label Phase)
billion cells per liter (BILL/L)Olanzapine (Open-label Treatment Period)
Baseline257.96 ± 64.25
Change-4.56 ± 49.94
Statistical analysis
  • Olanzapine (Open-label Treatment Period) · Wilcoxon (Mann-Whitney) · p = 0.024 (p-value represents change from baseline to endpoint for platelet count from Wilcoxon's signed-rank test.)
SecondaryChange From Baseline to Endpoint in Prolactin (Open-Label Phase)
Time frame:
Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Reported as:
Mean · microgram/Liter
Change From Baseline to Endpoint in Prolactin (Open-Label Phase)
microgram/LiterOlanzapine (Open-label Treatment Period)
Baseline21.64 ± 18.48
Change-3.41 ± 17.20
Statistical analysis
  • Olanzapine (Open-label Treatment Period) · Wilcoxon (Mann-Whitney) · p = <0.001 (p-value represents change from baseline to endpoint for prolactin from Wilcoxon's signed-rank test.)
SecondaryChange From Baseline to Endpoint in Uric Acid (Open-Label Phase)
Time frame:
Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Reported as:
Mean · micromole/Liter
Change From Baseline to Endpoint in Uric Acid (Open-Label Phase)
micromole/LiterOlanzapine (Open-label Treatment Period)
Baseline324.74 ± 89.39
Change14.73 ± 56.80
Statistical analysis
  • Olanzapine (Open-label Treatment Period) · Wilcoxon (Mann-Whitney) · p = <0.001 (p-value represents change from baseline to endpoint for uric acid from Wilcoxon's signed-rank test.)
SecondaryChange From Baseline to Endpoint in Glucose and Lipids (Cholesterol, Triglycerides, HDL Cholesterol, LDL Cholesterol) (Open-Label Phase)
Time frame:
Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Reported as:
Mean · millimole/Liter
Change From Baseline to Endpoint in Glucose and Lipids (Cholesterol, Triglycerides, HDL Cholesterol, LDL Cholesterol) (Open-Label Phase)
millimole/LiterOlanzapine (Open-label Treatment Period)
Baseline- Fasting Glucose (N=375)5.20 ± 0.57
Change- Fasting Glucose (N=375)0.06 ± 0.63
Baseline- Cholesterol (N=380)4.96 ± 1.08
Change- Cholesterol (N=380)0.05 ± 0.70
Baseline- Triglycerides (N=380)1.55 ± 1.06
Change- Triglycerides (N=380)0.10 ± 0.97
Baseline- LDL Cholesterol (N=378)2.88 ± 0.91
Change- LDL Cholesterol (N=378)0.06 ± 0.63
Baseline- HDL Cholesterol (N=380)1.39 ± 0.40
Change- HDL Cholesterol (N=380)-0.05 ± 0.24
Statistical analysis
  • Olanzapine (Open-label Treatment Period) · t-test, 2 sided · p = 0.047 (p-value represents change from baseline to endpoint for fasting glucose from t-tests on change.)
  • Olanzapine (Open-label Treatment Period) · t-test, 2 sided · p = 0.130 (p-value represents change from baseline to endpoint for cholesterol from t-tests on change.)
  • Olanzapine (Open-label Treatment Period) · t-test, 2 sided · p = 0.055 (p-value represents change from baseline to endpoint for triglycerides from t-tests on change.)
  • Olanzapine (Open-label Treatment Period) · t-test, 2 sided · p = 0.049 (p-value represents change from baseline to endpoint for LDL cholesterol from t-tests on change.)
  • Olanzapine (Open-label Treatment Period) · t-test, 2 sided · p = <0.001 (p-value represents change from baseline to endpoint for HDL cholesterol from t-tests on change.)
SecondaryChange From Baseline to Endpoint in ECG (Open-Label Phase)

Time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole, fixed correction factor (QTcF interval); Bazett-Corrected QT Interval (QTcB interval).

Time frame:
Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Reported as:
Mean · milliseconds
Change From Baseline to Endpoint in ECG (Open-Label Phase)
millisecondsOlanzapine (Open-label Treatment Period)
Baseline- QTcF410.09 ± 19.44
Change- QTcF1.80 ± 15.07
Baseline- QTcB421.72 ± 19.61
Change- QTcB1.76 ± 16.69
Statistical analysis
  • Olanzapine (Open-label Treatment Period) · t-test, 2 sided · p = 0.023 (p-value represents change from baseline to endpoint for QTcF from t-test.)
  • Olanzapine (Open-label Treatment Period) · t-test, 2 sided · p = 0.044 (p-value represents change from baseline to endpoint for QTcB from t-test.)
SecondaryChange From Baseline to Endpoint in Heart Rate (Open-Label Phase)
Time frame:
Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Reported as:
Mean · beats per minute
Change From Baseline to Endpoint in Heart Rate (Open-Label Phase)
beats per minuteOlanzapine (Open-label Treatment Period)
Baseline71.85 ± 11.64
Change0.06 ± 10.79
Statistical analysis
  • Olanzapine (Open-label Treatment Period) · t-test, 2 sided · p = 0.919 (p-value represents change from baseline to endpoint for heart rate from t-test.)
SecondaryPercentage of Participants With High Suicidality at Endpoint (Open-Label Phase)

The MINI module C (MINI-C) is a rating scale for severity of suicidal thoughts and behaviors. The MINI-C is composed of 12 Yes/No questions with variable scores assigned to each question. The scale ranges from 0 to 52 with higher scores indicating a greater presence of suicidal thoughts and/or behaviors. Based upon scores, suicidality is defined as Low (1-8), Medium (9-16), and High (\>=17).

Time frame:
Endpoint (Week 24)
Reported as:
Number · percentage of participants
Percentage of Participants With High Suicidality at Endpoint (Open-Label Phase)
percentage of participantsOlanzapine (Open-label Treatment Period)
Percentage of Participants With High Suicidality at Endpoint (Open-Label Phase)1.3
SecondaryNumber of Participants With Adverse Events (Open-Label Phase)

Please refer to the Adverse Event overview for details regarding adverse events and serious adverse events.

Time frame:
Baseline (End of Acute Phase/Week 6) through Endpoint (Week 24)
Reported as:
Number · participants
Number of Participants With Adverse Events (Open-Label Phase)
participantsOlanzapine (Open-label Treatment Period)
Serious14
Non-Serious209

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Olanzapine—6/343 (1.7%)238/343 (69.4%)
Placebo—7/171 (4.1%)88/171 (51.5%)
Olanzapine (Open Label Treatment Period—14/389 (3.6%)209/389 (53.7%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventOlanzapinePlaceboOlanzapine (Open Label Treatment Period
Bipolar I disorderPsychiatric disorders1/3432/1711/389
Suicidal ideationPsychiatric disorders1/3432/1711/389
Drug exposure during pregnancyInjury, poisoning and procedural complications0/3431/1710/389
AnxietyPsychiatric disorders0/3431/1710/389
DepressionPsychiatric disorders0/3431/1711/389
Depressive symptomPsychiatric disorders0/3431/1710/389
InsomniaPsychiatric disorders0/3431/1710/389
Completed suicidePsychiatric disorders0/3430/1712/389
Suicide attemptPsychiatric disorders0/3430/1712/389
PancreatitisGastrointestinal disorders1/3430/1711/389
Most frequent other events
Showing 10 of 21
Most frequent other events
EventOlanzapinePlaceboOlanzapine (Open Label Treatment Period
Weight increasedInvestigations59/3436/17167/389
SomnolenceNervous system disorders59/34311/17117/389
Increased appetiteMetabolism and nutrition disorders46/3434/17115/389
SedationNervous system disorders29/3434/1713/389
NasopharyngitisInfections and infestations24/3436/17120/389
ConstipationGastrointestinal disorders19/3435/1716/389
Dry mouthGastrointestinal disorders18/3436/1714/389
NauseaGastrointestinal disorders7/3438/1714/389
HeadacheNervous system disorders15/3438/17110/389
InsomniaPsychiatric disorders11/3438/1718/389

Baseline characteristics

Age Continuous
Age Continuous(years)OlanzapinePlaceboTotal
Mean35.93 ± 11.1334.96 ± 11.0235.61 ± 11.09
Sex: Female, Male
Sex: Female, Male(Participants)OlanzapinePlaceboTotal
Female20595300
Male13876214
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)OlanzapinePlaceboTotal
Caucasian362258
African18422
Hispanic639
East Asian282141423
Native American112
Region of Enrollment
Region of Enrollment(participants)OlanzapinePlaceboTotal
China14070210
Japan10452156
Korea, Republic of201030
Taiwan19928
United States603090
Age at onset, Bipolar I Disorder
Age at onset, Bipolar I Disorder(years)OlanzapinePlaceboTotal
Mean27.57 ± 10.9826.12 ± 9.9027.09 ± 10.64
08

Study locations

16 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beijing, 100088, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Changsha, 410008, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chengdu, 610041, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guang Zhou, 510370, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hangzhou, 310003, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Harbin, 150001, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kunming, 650032, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nanjing, 210029, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shanghai, 200030, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wu Han, 430060, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Xi'An, 710032, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hiroshima, 731-0501, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shiga, 525-0037, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 170-0002, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seongnam-Si, 463-707, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 110-744, Korea, Republic of
09

References and documents

Publications

  • Katagiri H, Tohen M, McDonnell DP, Fujikoshi S, Case M, Kanba S, Takahashi M, Gomez JC. Safety and efficacy of olanzapine in the long-term treatment of Japanese patients with bipolar I disorder, depression: an integrated analysis. Psychiatry Clin Neurosci. 2014 Jul;68(7):498-505. doi: 10.1111/pcn.12156. Epub 2014 Mar 4. PubMed 24417745 ↗
  • Katagiri H, Tohen M, McDonnell DP, Fujikoshi S, Case M, Kanba S, Takahashi M, Gomez JC. Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study. BMC Psychiatry. 2013 May 14;13:138. doi: 10.1186/1471-244X-13-138. PubMed 23672672 ↗
  • Tohen M, McDonnell DP, Case M, Kanba S, Ha K, Fang YR, Katagiri H, Gomez JC. Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. Br J Psychiatry. 2012 Nov;201(5):376-82. doi: 10.1192/bjp.bp.112.108357. Epub 2012 Aug 23. PubMed 22918966 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Mar 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2007
First posted
Aug 1, 2007
Start
Aug 2007
Primary completionActual
Mar 2010
CompletionActual
Jul 2010
Results first posted
May 26, 2011
Last update
May 26, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00510146
First posted
Aug 1, 2007
Start date
Aug 2007
Primary completion
Mar 2010
Completion
Jul 2010
Results posted
May 26, 2011
Last update
May 26, 2011

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5hrs, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olanzapine

Start the discussion